IL2 and type 1 diabetes mellitus: For type 1 diabetes model26, AT-MSCs treatment induced proliferation of regulatory T-cells, reducing Th1 and pro-inflammatory cytokine activity (IFN-γ, IL-2 and TNFα), whereas there was an increase in anti-inflammatory cytokines after 35 days of treatment.